Literature DB >> 15767921

[Endometrial choriocarcinoma in peri-menopausal women].

T Le Bret1, P Tranbaloc, J-L Benbunan, D Salet-Lizée, R Villet.   

Abstract

We report a case of a primary uterine choriocarcinoma associated with adenocarcinoma occurring during peri-menopausal age, and review the literature. The clinical course and the histopathology of the case were reviewed and a Medline literature search for other cases was performed. BHCG and analysis of uterine curettage provided the diagnosis of choriocarcinoma. Polychemotherapy, started immediately after the patient's clinical condition deteriorated, was successful. Colpohysterectomy and pelvic lymphadenectomy were performed 5 months later. Treatment was completed by vaginal curietherapy. Histopathologic examination of the surgical specimen revealed only adenocarcinoma. The patient was followed for 18 months without evidence of recurrence. The literature search revealed that primary forms are exceptional; the etiology is unknown. Treatment is based on polychemotherapy. Primary choriocarcinomas are rare tumours, associated with other histopathological forms. We document a case occurring during the peri-menopausal period and review the literature on this pathology. The very poor prognosis in the past has changed with early polychemotherapy.

Entities:  

Mesh:

Year:  2005        PMID: 15767921     DOI: 10.1016/s0368-2315(05)82674-2

Source DB:  PubMed          Journal:  J Gynecol Obstet Biol Reprod (Paris)        ISSN: 0150-9918


  2 in total

1.  The uterine choriocarcinoma in postmenopausal women: specificities of diagnosis and treatment.

Authors:  Ons Kaabia; Sawsen Meddeb; Mohamed Salah Rhim; Mohamed Bibi; Hedi Khairi
Journal:  Pan Afr Med J       Date:  2014-10-20

2.  Endometrial carcinoma with yolk sac tumor-like differentiation and elevated serum β-hCG: a case report and literature review.

Authors:  Mingliang Ji; Yan Lu; Lina Guo; Fengzhi Feng; Xirun Wan; Yang Xiang
Journal:  Onco Targets Ther       Date:  2013-10-24       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.